< Back

Immunophotonics announces 1st patient dosed in the United States

Immunophotonics, Inc., along with Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as the Principal Investigator and National Coordinating Investigator at the University of Louisville, announced that the first patient has been dosed with IP-001 in the United States under Immunophotonics’ Investigational New Drug (IND) application with the FDA.